Literature DB >> 18378719

Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.

Keith Miller1, Alexander J O'Neill, Mark H Wilcox, Eileen Ingham, Ian Chopra.   

Abstract

The development of resistance to linezolid (LZD) in gram-positive bacteria depends on the mutation of a single 23S rRNA gene, followed by homologous recombination and gene conversion of the other alleles. We sought to inhibit this process in Staphylococcus aureus using a range of antibacterial agents, including some that suppress recombination. A model for the rapid selection of LZD resistance was developed which allowed the selection of LZD-resistant mutants with G2576T mutations in all five copies of the 23S rRNA gene following only 5 days of subculture. The emergence of LZD-resistant isolates was delayed by exposing cultures to low concentrations of various classes of antibiotics. All antibiotic classes were effective in delaying the selection of LZD-resistant mutants and, with the exception of fusidic acid (FUS) and rifampin (RIF), prolonged the selection window from 5 to approximately 15 days. Inhibitors of DNA processing were no more effective than any other class of antibiotics at suppressing resistance development. However, the unrelated antimicrobials FUS and RIF were particularly effective at preventing the emergence of LZD resistance, prolonging the selection window from 5 to 25 days. The enhanced suppressive effect of FUS and RIF on the development of LZD resistance was lost in a recA-deficient host, suggesting that these drugs affect recA-dependent recombination. Furthermore, FUS and RIF were shown to be effective inhibitors of homologous recombination of a plasmid into the staphylococcal chromosome. We suggest that RIF or FUS in combination with LZD may have a role in preventing the emergence of LZD resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378719      PMCID: PMC2415777          DOI: 10.1128/AAC.01302-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  The ability of certain antimutagenic agents to prevent development of antibiotic resistance.

Authors:  S P Pillai; C A Pillai; D M Shankel; L A Mitscher
Journal:  Mutat Res       Date:  2001-09-20       Impact factor: 2.433

2.  Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.

Authors:  Scott A Lujan; Laura M Guogas; Heather Ragonese; Steven W Matson; Matthew R Redinbo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-13       Impact factor: 11.205

Review 3.  The susceptibility of conjugative resistance transfer in gram-negative bacteria to physicochemical and biochemical agents.

Authors:  P Viljanen; J Boratynski
Journal:  FEMS Microbiol Rev       Date:  1991-07       Impact factor: 16.408

Review 4.  Penicillin-binding protein-mediated resistance in pneumococci and staphylococci.

Authors:  H F Chambers
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

5.  Effect of subinhibitory concentrations of ampicillin on the R plasmid transfer in Escherichia coli.

Authors:  J C Palomares; R Prados; E J Perea
Journal:  Chemioterapia       Date:  1987-08

6.  A genetic and molecular characterization of the recA gene from Staphylococcus aureus.

Authors:  K W Bayles; E W Brunskill; J J Iandolo; L L Hruska; S Huang; P A Pattee; B K Smiley; R E Yasbin
Journal:  Gene       Date:  1994-09-15       Impact factor: 3.688

7.  Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.

Authors:  Michael Lobritz; Rebecca Hutton-Thomas; Steve Marshall; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus.

Authors:  N Fairweather; S Kennedy; T J Foster; M Kehoe; G Dougan
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

9.  Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.

Authors:  Venkata G Meka; Howard S Gold; Amy Cooke; Lata Venkataraman; George M Eliopoulos; Robert C Moellering; Stephen G Jenkins
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

10.  Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.

Authors:  Dilip Nathwani; Gavin D Barlow; Katherine Ajdukiewicz; Kirsteen Gray; John Morrison; Ben Clift; Anthony J France; Peter Davey
Journal:  J Antimicrob Chemother       Date:  2003-02       Impact factor: 5.790

View more
  10 in total

1.  The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.

Authors:  N Bourgeois-Nicolaos; T T Nguyen; G Defrance; L Massias; L Alavoine; A Lefort; V Noel; E Senneville; F Doucet-Populaire; F Mentré; A Andremont; X Duval
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Mechanisms of linezolid resistance among Staphylococci in a tertiary hospital.

Authors:  Inmaculada Quiles-Melero; Rosa Gómez-Gil; María Pilar Romero-Gómez; Ana María Sánchez-Díaz; Manuela de Pablos; Julio García-Rodriguez; Avelino Gutiérrez; Jesús Mingorance
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

Review 3.  Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Authors:  Prabhavathi Fernandes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

4.  In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

Authors:  Alexander A Firsov; Maria V Golikova; Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

5.  Polyphyletic emergence of linezolid-resistant staphylococci in the United States.

Authors:  Agnes Wong; Shilpa P Reddy; Davida S Smyth; Maria E Aguero-Rosenfeld; George Sakoulas; D Ashley Robinson
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

6.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

7.  The extent of migration of the Holliday junction is a crucial factor for gene conversion in Rhizobium etli.

Authors:  Mildred Castellanos; David Romero
Journal:  J Bacteriol       Date:  2009-06-05       Impact factor: 3.490

8.  Clinical results of linezolid in arthroplasty and trauma MRSA related infections.

Authors:  James Joel; Simon Matthew Graham; Adam Peckham-Cooper; Nectarios Korres; Helen Tsouchnica; Eleftherios Tsiridis
Journal:  World J Orthop       Date:  2014-04-18

9.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

10.  The processive kinetics of gene conversion in bacteria.

Authors:  Johan Paulsson; Meriem El Karoui; Monica Lindell; Diarmaid Hughes
Journal:  Mol Microbiol       Date:  2017-03-13       Impact factor: 3.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.